Table 3.

Multivariate analyses of overall survival for patients stratified by the probability of LNI.

The entire cohort
Probability of LNI, cut-off, %	patients, n	Adjusted HR (95%CI), NRN (continuous)	p-value	Adjusted HR (95%CI), NRN (≥12 vs.<12)	p-value
≥2	26,686	0.985 (0.969–1.005)	0.155	0.772 (0.599–1.078)	0.147
≥9	15,457	0.988 (0.97–1.006)	0.19	0.827 (0.619–1.106)	0.2
≥16	11,148	0.983 (0.963–1.004)	0.111	0.763 (0.547–1.065)	0.112
≥23	8,691	0.973 (0.949–1.002)	0.122	0.699 (0.478–1.022)	0.064
≥30	7,113	0.972 (0.951–1.002)	0.109	0.577 (0.407–0.818)	0.002
≥37	5,881	0.967 (0.944–0.99)	0.005	0.534 (0.365–0.782)	0.001
≥44	4,589	0.962 (0.937–0.987)	0.003	0.529 (0.352–0.794)	0.002
≥51	3,512	0.951 (0.921–0.981)	0.002	0.445 (0.273–0.727)	0.001
≥58	2,549	0.948 (0.915–0.982)	0.003	0.342 (0.19–0.614)	<0.001
The PSM cohort
≥2	12,152	0.985 (0.967–1.004)	0.115	0.723 (0.539–0.092)	0.143
≥9	7,853	0.991 (0.97–1.012)	0.383	0.806 (0.576–1.129)	0.209
≥16	6,010	0.978 (0.955–1.013)	0.077	0.673 (0.463–1.142)	0.134
≥23	4,860	0.967 (0.94–1.023)	0.095	0.637 (0.418–1.109)	0.052
≥30	4,077	0.973 (0.95–1.008)	0.056	0.575 (0.395–0.825)	0.015
≥37	3,449	0.961 (0.935–0.987)	0.004	0.453 (0.298–0.689)	<0.001
≥44	2,783	0.961 (0.934–0.989)	0.006	0.451 (0.289–0.706)	<0.001
≥51	2,173	0.950 (0.917–0.983)	0.004	0.379 (0.222–0.646)	<0.001
≥58	1,626	0.945 (0.908–0.983)	0.005	0.282 (0.150–0.531)	<0.001

Adjusted for Gleason score at biopsy, clinical T stage, PSA, age at diagnosis, percentage of positive cores, and lymph node invasion.

LNI, lymph node invasion; NRN, number of removed nodes; HR, hazard ratio; CI, confidence interval.